Posted by Michael Wonder on 30 May 2024
FDA use of “proxies” to expedite drug approvals not supported by evidence, analysis finds
28 May 2024 - In the world of drug development, there has been a recent movement to speed clinical trials of experimental treatments to faster conclusions, with the goal of getting new medicines to patients sooner.
That movement relies on what are known as “surrogate markers” (or proxies), which are possible predictors of a disease outcome that are supposed to forecast improvement of the associated disease months or years in advance.
